Cargando…
Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up
PURPOSE: Multimodal therapies have significantly improved prognosis in glioma. However, in particular radiotherapy may induce long-term neurotoxicity compromising patients’ neurocognition and quality of life. The present prospective multicenter study aimed to evaluate associations of multimodal trea...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522752/ https://www.ncbi.nlm.nih.gov/pubmed/37648934 http://dx.doi.org/10.1007/s11060-023-04419-y |
_version_ | 1785110421253914624 |
---|---|
author | Pertz, Milena Schlömer, Sabine Seidel, Clemens Hentschel, Bettina Löffler, Markus Schackert, Gabriele Krex, Dietmar Juratli, Tareq Tonn, Joerg Christian Schnell, Oliver Vatter, Hartmut Simon, Matthias Westphal, Manfred Martens, Tobias Sabel, Michael Bendszus, Martin Dörner, Nils Wick, Antje Fliessbach, Klaus Hoppe, Christian Klingner, Marcel Felsberg, Jörg Reifenberger, Guido Gramatzki, Dorothee Weller, Michael Schlegel, Uwe |
author_facet | Pertz, Milena Schlömer, Sabine Seidel, Clemens Hentschel, Bettina Löffler, Markus Schackert, Gabriele Krex, Dietmar Juratli, Tareq Tonn, Joerg Christian Schnell, Oliver Vatter, Hartmut Simon, Matthias Westphal, Manfred Martens, Tobias Sabel, Michael Bendszus, Martin Dörner, Nils Wick, Antje Fliessbach, Klaus Hoppe, Christian Klingner, Marcel Felsberg, Jörg Reifenberger, Guido Gramatzki, Dorothee Weller, Michael Schlegel, Uwe |
author_sort | Pertz, Milena |
collection | PubMed |
description | PURPOSE: Multimodal therapies have significantly improved prognosis in glioma. However, in particular radiotherapy may induce long-term neurotoxicity compromising patients’ neurocognition and quality of life. The present prospective multicenter study aimed to evaluate associations of multimodal treatment with neurocognition with a particular focus on hippocampal irradiation. METHODS: Seventy-one glioma patients (WHO grade 1–4) were serially evaluated with neurocognitive testing and quality of life questionnaires. Prior to (baseline) and following further treatment (median 7.1 years [range 4.6–11.0] after baseline) a standardized computerized neurocognitive test battery (NeuroCog FX) was applied to gauge psychomotor speed and inhibition, verbal short-term memory, working memory, verbal and non-verbal memory as well as verbal fluency. Mean ipsilateral hippocampal radiation dose was determined in a subgroup of 27 patients who received radiotherapy according to radiotherapy plans to evaluate its association with neurocognition. RESULTS: Between baseline and follow-up mean performance in none of the cognitive domains significantly declined in any treatment modality (radiotherapy, chemotherapy, combined radio-chemotherapy, watchful-waiting), except for selective attention in patients receiving chemotherapy alone. Apart from one subtest (inhibition), mean ipsilateral hippocampal radiation dose > 50 Gy (Dmean) as compared to < 10 Gy showed no associations with long-term cognitive functioning. However, patients with Dmean < 10 Gy showed stable or improved performance in all cognitive domains, while patients with > 50 Gy numerically deteriorated in 4/8 domains. CONCLUSIONS: Multimodal glioma therapy seems to affect neurocognition less than generally assumed. Even patients with unilateral hippocampal irradiation with > 50 Gy showed no profound cognitive decline in this series. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11060-023-04419-y. |
format | Online Article Text |
id | pubmed-10522752 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-105227522023-09-28 Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up Pertz, Milena Schlömer, Sabine Seidel, Clemens Hentschel, Bettina Löffler, Markus Schackert, Gabriele Krex, Dietmar Juratli, Tareq Tonn, Joerg Christian Schnell, Oliver Vatter, Hartmut Simon, Matthias Westphal, Manfred Martens, Tobias Sabel, Michael Bendszus, Martin Dörner, Nils Wick, Antje Fliessbach, Klaus Hoppe, Christian Klingner, Marcel Felsberg, Jörg Reifenberger, Guido Gramatzki, Dorothee Weller, Michael Schlegel, Uwe J Neurooncol Research PURPOSE: Multimodal therapies have significantly improved prognosis in glioma. However, in particular radiotherapy may induce long-term neurotoxicity compromising patients’ neurocognition and quality of life. The present prospective multicenter study aimed to evaluate associations of multimodal treatment with neurocognition with a particular focus on hippocampal irradiation. METHODS: Seventy-one glioma patients (WHO grade 1–4) were serially evaluated with neurocognitive testing and quality of life questionnaires. Prior to (baseline) and following further treatment (median 7.1 years [range 4.6–11.0] after baseline) a standardized computerized neurocognitive test battery (NeuroCog FX) was applied to gauge psychomotor speed and inhibition, verbal short-term memory, working memory, verbal and non-verbal memory as well as verbal fluency. Mean ipsilateral hippocampal radiation dose was determined in a subgroup of 27 patients who received radiotherapy according to radiotherapy plans to evaluate its association with neurocognition. RESULTS: Between baseline and follow-up mean performance in none of the cognitive domains significantly declined in any treatment modality (radiotherapy, chemotherapy, combined radio-chemotherapy, watchful-waiting), except for selective attention in patients receiving chemotherapy alone. Apart from one subtest (inhibition), mean ipsilateral hippocampal radiation dose > 50 Gy (Dmean) as compared to < 10 Gy showed no associations with long-term cognitive functioning. However, patients with Dmean < 10 Gy showed stable or improved performance in all cognitive domains, while patients with > 50 Gy numerically deteriorated in 4/8 domains. CONCLUSIONS: Multimodal glioma therapy seems to affect neurocognition less than generally assumed. Even patients with unilateral hippocampal irradiation with > 50 Gy showed no profound cognitive decline in this series. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11060-023-04419-y. Springer US 2023-08-30 2023 /pmc/articles/PMC10522752/ /pubmed/37648934 http://dx.doi.org/10.1007/s11060-023-04419-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Pertz, Milena Schlömer, Sabine Seidel, Clemens Hentschel, Bettina Löffler, Markus Schackert, Gabriele Krex, Dietmar Juratli, Tareq Tonn, Joerg Christian Schnell, Oliver Vatter, Hartmut Simon, Matthias Westphal, Manfred Martens, Tobias Sabel, Michael Bendszus, Martin Dörner, Nils Wick, Antje Fliessbach, Klaus Hoppe, Christian Klingner, Marcel Felsberg, Jörg Reifenberger, Guido Gramatzki, Dorothee Weller, Michael Schlegel, Uwe Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up |
title | Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up |
title_full | Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up |
title_fullStr | Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up |
title_full_unstemmed | Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up |
title_short | Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up |
title_sort | long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522752/ https://www.ncbi.nlm.nih.gov/pubmed/37648934 http://dx.doi.org/10.1007/s11060-023-04419-y |
work_keys_str_mv | AT pertzmilena longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT schlomersabine longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT seidelclemens longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT hentschelbettina longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT lofflermarkus longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT schackertgabriele longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT krexdietmar longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT juratlitareq longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT tonnjoergchristian longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT schnelloliver longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT vatterhartmut longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT simonmatthias longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT westphalmanfred longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT martenstobias longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT sabelmichael longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT bendszusmartin longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT dornernils longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT wickantje longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT fliessbachklaus longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT hoppechristian longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT klingnermarcel longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT felsbergjorg longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT reifenbergerguido longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT gramatzkidorothee longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT wellermichael longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT schlegeluwe longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup AT longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup |